Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q4LDG9
UPID:
DNAL1_HUMAN
Alternative names:
-
Alternative UPACC:
Q4LDG9; B2RD38; Q5JPB7; Q9BS43
Background:
Dynein axonemal light chain 1 plays a crucial role in ciliary motility, essential for respiratory health and embryonic development. It is a key component of the outer arm dynein, which drives the force for cilia movement. This protein's function is vital for the airways' ciliary operation and for establishing the body's left-right asymmetry.
Therapeutic significance:
Mutations in Dynein axonemal light chain 1 are linked to Primary Ciliary Dyskinesia 16, a condition marked by respiratory infections and potential fertility issues. Understanding its role could lead to novel treatments for this and related ciliary disorders.